Key Details
Price
$53.00Last Dividend
$2.04TTM Dividend Yield
3.84%PE Ratio
21.21Annual ROE
7.61%Beta
0.12Events Calendar
Next earnings date:
Apr 24, 2025Recent quarterly earnings:
Jan 30, 2025Recent annual earnings:
Jan 30, 2025Next ex-dividend date:
N/ARecent ex-dividend date:
May 9, 2024Next split:
N/ARecent split:
Sep 30, 2013Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Events
Dividend per share
Dividend yield
Other
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
MITEM PHARMA, a pharmaceutical company based in France that focuses on Drugs of Major Therapeutic Interest (DMTI), has announced the acquisition of FLISINT®, a treatment for infectious diseases, from SANOFI WINTHROP INDUSTRIE in Gentilly, France. FLISINT® (fumagillin) is known as the only effective treatment for infections caused by Enterocytozoon bieneusi microsporidia, which can occur in patients with weakened immune systems.
On February 3, 2025, Sanofi revealed that it is buying back 2.3% of its shares from L'Oréal Paris, a shareholder it has worked with for a long time.
Sarclisa is the first treatment that targets CD38 to be approved in China for patients with newly diagnosed multiple myeloma who cannot undergo a transplant.
Sanofi will hold its Q4 2024 Results Conference Call on January 30, 2025, at 9:00 AM ET. Key company participants include Thomas Larsen, Paul Hudson, and Francois Roger, among others. Investors and analysts can access the presentation slides on sanofi.com.
SNY did not meet its earnings and sales predictions for the fourth quarter. However, it anticipates that earnings will improve in 2025.
Sanofi's CEO, Paul Hudson, appears on 'Squawk Box' to talk about the company's quarterly earnings, future expectations for 2025, their drug development plans, and decisions regarding dividends and stock buybacks. He also shares his views on the confirmation hearing of RFK Jr. and other topics.
On Thursday, French pharmaceutical company Sanofi announced that its fourth-quarter profit matched analysts' expectations. The company also revealed plans to repurchase 5 billion euros ($5.21 billion) worth of shares this year to boost investor confidence in its drug development projects.
Paul Hudson, the CEO of Sanofi, mentioned that his company is looking into new obesity medications, highlighting that finding long-term weight loss solutions is the next challenge.
The recent decision has made Sanofi's Sarclisa the first anti-CD38 treatment available for patients with front-line multiple myeloma who cannot undergo a transplant in the EU.
Sarclisa has been approved in the EU as the first anti-CD38 treatment used alongside the standard VRd therapy for patients with newly diagnosed multiple myeloma who cannot undergo a transplant.
FAQ
- What is the ticker symbol for Sanofi?
- Does Sanofi pay dividends?
- What sector is Sanofi in?
- What industry is Sanofi in?
- What country is Sanofi based in?
- When did Sanofi go public?
- Is Sanofi in the S&P 500?
- Is Sanofi in the NASDAQ 100?
- Is Sanofi in the Dow Jones?
- When was Sanofi's last earnings report?
- When does Sanofi report earnings?